The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Abstract
Compared to best-in-class GLP-1 mono-agonists, unimolecular co-agonists of GLP-1 and GIP with optimized pharmacokinetics enhance glycemic and metabolic benefits in mammals.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This was the first human trial to demonstrate that GLP-1R/GCGR co-agonism could be a suitable option for weight loss maintenance, and further, added clinical validation that glucagon agonism could significantly contribute to the regulation of energy balance in an obese setting (Figure 3).”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [85]
In the citing paper
“It acts on GIP receptor five times over GLP-1 receptor [50].”
From The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update. (2024) · cites this paper as [50]
In the citing paper
“with preclinical and early-phase clinical trials supporting their potential as next-generation obesity treatments [16–23].”
From Triple Agonism Based Therapies for Obesity (2025) · cites this paper as [20]
In the citing paper
“Matthias Tschöp and his team discovered that dual agonists targeting both GLP-1 and GIP receptors (GIPR) are more effective in treating diabetes than those targeting only GLP-1R. These dual agonists were found to reduce blood sugar and increase insulin secretion in mice, monkeys, and humans.27”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [27]
In the citing paper
“a GLP-1/GIP dual agonist produced greater reductions in body weight than GLP-1 monoagonists alone in DIO mice [46, 47, 89].”
From Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes (2024) · cites this paper as [89]
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Beige Adipocytes Are a Distinct Type of Thermogenic Fat Cell in Mouse and Human
Wu, J., Boström, P., Sparks, L. M., Ye, L., Choi, J. H., Giang, A.-H., Khandekar, M., Virtanen, K. A., Nuutila, P., Schaart, G., et al. (2012) · Cell · doi:10.1016/j.cell.2012.05.016 · Cited by 3,319
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Self-citationNauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Inhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963 · cited 1×
“Finally, preclinical observations with GIPR knockout rodents reported less weight gain on a high-fat diet challenge and an overall protection from glycemic disturbances (6, 7), which was also observed with pharmacological GIP antagonism (9–11) and with transgenic ablation of GIP-producing intestinal K cells (8).”
BackgroundSystematic review and meta-analysis of psychological therapies for children with chronic pain
Fisher, E., Heathcote, L., Palermo, T. M., de C Williams, A. C., Lau, J., & Eccleston, C. (2014) · Journal of Pediatric Psychology · doi:10.1093/jpepsy/jsu008 · Cited by 710
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641
Self-citationMiyawaki, K., Yamada, Y., Yano, H., Niwa, H., Ban, N., Ihara, Y., Kubota, A., Fujimoto, S., Kajikawa, M., Kuroe, A., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.14843 · Cited by 454
Peptide YY3–36 and Glucagon-Like Peptide-17–36 Inhibit Food Intake Additively
Neary, N. M., Small, C. J., Druce, M. R., Park, A. J., Ellis, S. M., Semjonous, N. M., Dakin, C. L., Filipsson, K., Wang, F., Kent, A. S., et al. (2005) · Endocrinology · doi:10.1210/en.2005-0237 · Cited by 371
Targeted estrogen delivery reverses the metabolic syndrome
Finan, B., Yang, B., Ottaway, N., Stemmer, K., Müller, T. D., Yi, C.-X., Habegger, K., Schriever, S. C., García-Cáceres, C., Kabra, D. G., et al. (2012) · Nature Medicine · doi:10.1038/nm.3009 · Cited by 337
Self-citation
Cited by
Peptide therapeutics: current status and future directions
Fosgerau, K., & Hoffmann, T. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2014.10.003 · Cited by 3,030
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170
“An acylated co-agonist that recognizes both the GLP-1 and GIP receptors produced greater metabolic benefits (glucose control and weight loss) in preclinical studies (including acute studies in non-human primates) relative to GLP-1R agonism alone (Finan et al., 2013).”
BackgroundSelf-citationTherapeutic peptides: Historical perspectives, current development trends, and future directions
Lau, J. L., & Dunn, M. K. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.06.052 · Cited by 1,879
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
“Several studies in mice [465,467,685,774] and humans [783e787] have failed to detect changes in energy expenditure following chronic or acute peripheral treatment with different GLP-1R agonists.”
BackgroundSelf-citationAnti-obesity drug discovery: advances and challenges
Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00337-8 · Cited by 1,021
Self-citation
Metadata
- Authors
- Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., Lockie, S. H., Smiley, D. L., Gelfanov, V., Yang, B., Hofmann, S., Bruemmer, D., Drucker, D. J., Pfluger, P. T., Perez-Tilve, D., Gidda, J., Vignati, L., Zhang, L., Hauptman, J. B., Lau, M., Brecheisen, M., Uhles, S., Riboulet, W., Hainaut, E., Sebokova, E., Conde-Knape, K., Konkar, A., DiMarchi, R. D., & Tschöp, M. H.
- Affiliations
- Helmholtz Munich (DE)
- Indiana University Bloomington (US)
- University of Cincinnati (US)
- Karolinska Institutet (SE)
- Monash University (AU)
- Technical University of Munich (DE)
- University of Kentucky (US)
- Mount Sinai Hospital (CA)
- Metabolic Diseases Institute, Division of Endocrinology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH 45237, USA.
- Marcadia Biotech, Carmel, IN 46032, USA.
- F. Hoffmann-La Roche AG (CH)
- F. Hoffmann–La Roche Ltd., Basel 4070, Switzerland.
- Corresponding author
- Finan, Brian
- Ma, Tao
- DiMarchi, Richard D.
- Tschöp, Matthias H.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2013-10-30
- Volume
- 5
- Issue
- 209
- Pages
- 209ra151-209ra151
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2149717292
- Cited by
- 696
- References
- 44
- Citations by year
- 2026: 46 · 2025: 56 · 2024: 91 · 2023: 71 · 2022: 54 · 2021: 64 · 2020: 56 · 2019: 63 · 2018: 50 · 2017: 40 · 2016: 43 · 2015: 36 · 2014: 22 · 2013: 4
- FWCI
- 27.53
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Site cant be reached (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, obesity, type 2 diabetes, insulin resistance, fat mass reduction, PEGylation, lipid modification, pharmacokinetics, impaired glucose tolerance, db/db mice, Zucker diabetic fatty rats, Macaca fascicularis, gastrointestinal adverse effects
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Exenatide, Acylation, Adolescent, Adult, Aged, Animals, Haplorhini, Diabetes Mellitus, Type 2, Female, Gastric Inhibitory Polypeptide, Glucose Tolerance Test, Humans, Hyperglycemia, Insulin, Male, Middle Aged, Peptides, Receptors, Gastrointestinal Hormone, Rodentia, Venoms, Weight Loss, Treatment Outcome, Receptors, Glucagon, Mice, Rats, Glucagon-Like Peptide 1, Incretins, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans. https://app.cochat.ai/papers/10.1126/scitranslmed.3007218
- The paper
- Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., Lockie, S. H., Smiley, D. L., Gelfanov, V., Yang, B., Hofmann, S., Bruemmer, D., Drucker, D. J., Pfluger, P. T., Perez-Tilve, D., . . . Tschöp, M. H. (2013). Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.3007218
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.